TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Researchers studying older adults and mice linked reduced NRF2 activity in oligodendrocytes—the cells that maintain myelin around nerve fibers—to abnormal myelin, loss of large nerve fibers and faster cognitive decline. The findings identify a possible treatment target, but they do not show that existing NRF2-targeting drugs can prevent age-related decline.
A study published in Nature Medicine links changes in oligodendrocytes—brain cells that maintain the insulating coating around nerve fibers—to faster cognitive decline in older adults. Researchers from the University of Edinburgh and the UK Dementia Research Institute reported related changes in human brain tissue and found that reducing a protective protein in these cells produced similar effects in mice; the work points to a possible research target, not a proven treatment.
The human findings draw on the Lothian Birth Cohort 1936, whose participants have had their cognitive abilities tracked over many decades. From 1,091 people enrolled, 866 completed additional testing after age 70. Between ages 70 and 82, assessments measured memory, processing speed and spatial reasoning. Most participants experienced some decline, but the pace varied.
Researchers examined brain tissue collected after death from a subset of the cohort. People whose thinking abilities had declined more quickly tended to have fewer large nerve fibers and an abnormal accumulation of myelin, the coating that helps electrical signals travel along those fibers. The tissue patterns were associated with the rate of decline, rather than performance on a cognitive test at one age.
The team also found lower levels of NRF2, a protein involved in cellular defenses, in oligodendrocytes from people with more severe decline. In mice, specifically reducing NRF2 in these cells led to excess myelin, loss of large nerve fibers and less improvement in cognitive performance as the animals aged. The animal experiments support a possible causal role for NRF2 disruption in the observed changes, but do not establish that the same sequence causes human cognitive decline.
A New Target in Aging Brain Research
The study challenges the assumption that oligodendrocytes are invariably protective. These cells are needed to maintain myelin, but the findings suggest that age-related dysfunction in the cells may also harm nerve fibers. If future research confirms that link, it could broaden scientists’ understanding of how changes beyond the neurons themselves contribute to declining memory and thinking skills.
The results also point to NRF2 as a possible treatment target. The source report notes that drugs acting on this pathway are used for other neurological conditions, including multiple sclerosis, and that previous studies have reported cognitive improvements in people with MS after increasing NRF2 activity. Those findings do not show that the same drugs would help older adults with age-related decline. Safety, effectiveness and the appropriate patients would need to be tested directly.
As an affiliate, we earn on qualifying purchases.
Cohort Data and Mouse Experiments
The study combines two kinds of evidence. Long-term cognitive records from the Lothian Birth Cohort allowed the researchers to compare brain tissue findings with changes in participants’ abilities over time. Post-mortem tissue can reveal structural and cellular differences, but by itself cannot show when those changes began or whether they caused the decline.
The researchers then tested a proposed mechanism in mice by lowering NRF2 specifically in oligodendrocytes. The resulting nerve-fiber and myelin changes resembled those seen in the human tissue. This offers experimental support for the mechanism, while leaving open how closely the mouse results translate to people. The study’s human observations and animal experiments are complementary, but neither amounts to a clinical trial of an NRF2-targeting treatment for age-related cognitive decline.
“As the prevalence of cognitive decline is rising with an aging population and no current treatments exist, we are excited about this work as it points to a potential strategy for new therapeutic strategies to preserve cognitive ability in aging.”
— Veronique Miron, MRC Senior Non-Clinical Fellow and UK Dementia Research Institute group leader at the University of Edinburgh and St. Michael’s Hospital, part of Unity Health Toronto
oligodendrocyte support supplement
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Human Treatment Benefits Remain Unknown
The study does not establish that reduced NRF2 activity is the cause of cognitive decline in people, or that increasing NRF2 would prevent or reverse it. The human tissue was examined after participants had died, so the timing and direction of the relationship remain uncertain. The supplied report does not specify how many tissue samples were analyzed or provide effect sizes for the reported associations.
It is also unclear whether drugs used for other neurological conditions would act safely and effectively on oligodendrocytes in older adults. Results from people with multiple sclerosis cannot be assumed to apply to age-related cognitive decline. The report identifies a biological pathway for further study, but describes no clinical trial testing such a treatment in this population.
As an affiliate, we earn on qualifying purchases.
Testing the NRF2 Treatment Hypothesis
The next step is further research to determine how NRF2 activity changes in oligodendrocytes as people age and whether those changes precede damage to myelin and nerve fibers. Studies will also need to establish whether medications that act on the pathway can influence the relevant brain cells in older adults.
Before an existing drug could be considered a treatment for age-related cognitive decline, researchers would need evidence from trials assessing its safety and effects on cognitive outcomes in the intended population. Until then, the findings should be understood as a potential research direction, not a basis for changing medication or assuming that cognitive decline can be prevented through NRF2-targeting drugs.
cognitive decline support supplement
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
Which brain cells are linked to the decline?
The study focused on oligodendrocytes, cells that produce and maintain myelin, the insulating material around nerve fibers.
What did researchers observe in human brain tissue?
In tissue from a subset of participants, faster cognitive decline was associated with fewer large nerve fibers, abnormal myelin buildup and lower NRF2 levels in oligodendrocytes.
Does the study show that a drug can prevent cognitive decline?
No. The research identifies a possible pathway for future treatment studies. It does not report a clinical trial showing that an NRF2-targeting drug prevents or treats age-related cognitive decline.
Why were mice included in the research?
Researchers reduced NRF2 in mouse oligodendrocytes to test whether the protein might be involved in the brain changes. The mice developed excess myelin, lost large nerve fibers and showed less improvement in cognitive performance as they aged. These results do not prove the same effects occur in people.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
